Next Article in Journal
TRIM19/PML Restricts HIV Infection in a Cell Type-Dependent Manner
Next Article in Special Issue
Exploring Reovirus Plasticity for Improving Its Use as Oncolytic Virus
Previous Article in Journal
Ebola Virus Infections in Nonhuman Primates Are Temporally Influenced by Glycoprotein Poly-U Editing Site Populations in the Exposure Material
Previous Article in Special Issue
Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy
Article

Newcastle Disease Virus: Potential Therapeutic Application for Human and Canine Lymphoma

1
Faculty of Veterinary Medicine and Animal Husbandry, National Autonomous University of Mexico, Mexico City 04510, Mexico
2
Medical Research Unit, Oncology Hospital, Mexican Institute for Social Security, Mexico City 06720, Mexico
3
Biomedical Cancer Research Unit, National Cancer Institute and Physics Institute, National Autonomous University of Mexico, Mexico City 14080, Mexico
4
Pathology Department, Spanish Hospital, Mexico City 11520, Mexico
5
Hematology Department, National Cancer Institute, Mexico City 14080, Mexico
*
Authors to whom correspondence should be addressed.
Academic Editors: E. Antonio Chiocca and Martine L. M. Lamfers
Received: 1 September 2015 / Revised: 17 November 2015 / Accepted: 24 November 2015 / Published: 23 December 2015
(This article belongs to the Special Issue Oncolytic Viruses)
Research on oncolytic viruses has mostly been directed towards the treatment of solid tumors, which has yielded limited information regarding their activity in hematological cancer. It has also been directed towards the treatment of humans, yet veterinary medicine may also benefit. Several strains of the Newcastle disease virus (NDV) have been used as oncolytics in vitro and in a number of in vivo experiments. We studied the cytolytic effect of NDV-MLS, a low virulence attenuated lentogenic strain, on a human large B-cell lymphoma cell line (SU-DHL-4), as well as on primary canine-derived B-cell lymphoma cells, and compared them to healthy peripheral blood mononuclear cells (PBMC) from both humans and dogs. NDV-MLS reduced cell survival in both human (42% ± 5%) and dog (34% ± 12%) lymphoma cells as compared to untreated controls. No significant effect on PBMC was seen. Cell death involved apoptosis as documented by flow-cytometry. NDV-MLS infections of malignant lymphoma tumors in vivo in dogs were confirmed by electron microscopy. Early (24 h) biodistribution of intravenous injection of 1 × 1012 TCID50 (tissue culture infective dose) in a dog with T-cell lymphoma showed viral localization only in the kidney, the salivary gland, the lung and the stomach by immunohistochemistry and/or endpoint PCR. We conclude that NDV-MLS may be a promising agent for the treatment of lymphomas. Future research is needed to elucidate the optimal therapeutic regimen and establish appropriate biosafety measures. View Full-Text
Keywords: Newcastle disease virus; lymphoma; oncolytic virus Newcastle disease virus; lymphoma; oncolytic virus
Show Figures

Figure 1

MDPI and ACS Style

Sánchez, D.; Pelayo, R.; Medina, L.A.; Vadillo, E.; Sánchez, R.; Núñez, L.; Cesarman-Maus, G.; Sarmiento-Silva, R.E. Newcastle Disease Virus: Potential Therapeutic Application for Human and Canine Lymphoma. Viruses 2016, 8, 3. https://0-doi-org.brum.beds.ac.uk/10.3390/v8010003

AMA Style

Sánchez D, Pelayo R, Medina LA, Vadillo E, Sánchez R, Núñez L, Cesarman-Maus G, Sarmiento-Silva RE. Newcastle Disease Virus: Potential Therapeutic Application for Human and Canine Lymphoma. Viruses. 2016; 8(1):3. https://0-doi-org.brum.beds.ac.uk/10.3390/v8010003

Chicago/Turabian Style

Sánchez, Diana, Rosana Pelayo, Luis A. Medina, Eduardo Vadillo, Rogelio Sánchez, Luis Núñez, Gabriela Cesarman-Maus, and Rosa E. Sarmiento-Silva 2016. "Newcastle Disease Virus: Potential Therapeutic Application for Human and Canine Lymphoma" Viruses 8, no. 1: 3. https://0-doi-org.brum.beds.ac.uk/10.3390/v8010003

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop